Naidoo K., Lessells RJ., Dorward J., Moosa MYS., Sookrajh Y., Moodley P., Drain PK., Garrett N.

The integrase strand transfer inhibitor, dolutegravir (DTG), is widely used in first- and second-line antiretroviral therapy (ART) regimens in South Africa. We describe an adult with virological failure on second-line tenofovir/lamivudine/dolutegravir (TLD2) and rapid emergence of DTG resistance within 3 months, while receiving rifapentine-based tuberculosis preventive therapy.

Rapid emergence of dolutegravir resistance on second-line dolutegravir-based ART

Naidoo K., Lessells RJ., Dorward J., Moosa MYS., Sookrajh Y., Moodley P., Drain PK., Garrett N.

DOI

Type

Publication Date

Volume